Cytokinetics, Incorporated
CYTK
$39.48
$0.330.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -589.53M | -576.40M | -545.28M | -530.60M | -526.24M |
| Total Depreciation and Amortization | 9.53M | 13.48M | 12.93M | 12.38M | 11.89M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 148.44M | 119.73M | 102.87M | 100.11M | 96.93M |
| Change in Net Operating Assets | 35.66M | 38.83M | 30.43M | -3.44M | 3.09M |
| Cash from Operations | -395.89M | -404.36M | -399.06M | -421.55M | -414.33M |
| Capital Expenditure | -3.91M | -2.69M | -2.21M | -1.01M | -1.42M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -549.19M | -742.68M | -625.07M | 107.41M | 240.67M |
| Cash from Investing | -553.10M | -745.37M | -627.28M | 106.40M | 239.25M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -9.62M | -6.93M | -4.25M | -1.58M | -858.00K |
| Issuance of Common Stock | 759.86M | 922.40M | 920.52M | 302.32M | 182.69M |
| Repurchase of Common Stock | -19.63M | -18.45M | -18.45M | -18.45M | -10.52M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 200.00M | 200.00M | 250.00M | 50.00M | 50.00M |
| Cash from Financing | 930.61M | 1.10B | 1.15B | 332.29M | 221.32M |
| Foreign Exchange rate Adjustments | 209.00K | -103.00K | 23.00K | 7.00K | -20.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -18.17M | -52.80M | 121.50M | 17.14M | 46.22M |